Physician profile
Muhammad Shaikh
NPI 1396705752
$645.36
in general payments reported to CMS, 2019-2025
17 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $12.74 · 2021: $34.38 · 2022: $38.23 · 2023: $113 · 2024: $134 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $385 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $384.82 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $104.30 | 2022-2023 | Myrbetriq, Veozah |
| Exact Sciences Corporation | $88.29 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $77.60 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $46.31 | 2019 | |
| Sanofi-Aventis U.S. LLC | $42.30 | 2024-2025 | |
| Glaxosmithkline, LLC. | $40.42 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Inspire Medical Systems, INC. | $35.74 | 2025 | Inspire |
| Lilly USA, LLC | $35.38 | 2019-2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.97 | 2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $23.56 | 2022 | |
| Pfizer INC. | $22.73 | 2021 | |
| Corium, LLC | $21.63 | 2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $20.55 | 2019 | |
| Merck Sharp & Dohme LLC | $18.70 | 2024 | Verquvo |
| Abbvie INC. | $14.88 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.35 | 2025 | Breztri |
| Gilead Sciences, INC. | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.